STOCK TITAN
  1. Home
  2. Sec-filings
  3. TWST
  4. [Form 4] Twist Bioscience Corp Insider Trading Activity

Twist Bioscience (TWST) legal chief sells stock under 10b5-1 plan

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported that Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, sold 14,205 shares of common stock on August 19, 2026, at $129.75 per share in an open-market or private transaction. Following the sale, he directly holds 75,661 shares. The transaction was effected under a previously adopted Rule 10b5-1 trading plan dated February 17, 2026.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Cho Dennis
Role See Remarks
Sold 14,205 shs ($1.84M)
Type Security Shares Price Value
Sale Common Stock F1 14,205 $129.75 $1.84M
Holdings After Transaction: Common Stock — 75,661 shares (Direct)
Footnotes (1)
  1. F1. The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 17, 2026.
Shares sold 14,205 shares of Common Stock Sale on August 19, 2026 reported on Form 4
Sale price per share $129.75 per share Transaction price for the 14,205 shares sold
Shares owned after transaction 75,661 shares of Common Stock Direct ownership following the August 19, 2026 sale
Rule 10b5-1 plan adoption date February 17, 2026 Date Dennis Cho adopted the trading plan used for this sale
Net shares sold (summary) 14,205 shares Net-sell direction from transaction summary
Rule 10b5-1 trading plan regulatory
"The transaction ... is effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Sale in open market or private transaction market
"transaction_code_description: Sale in open market or private transaction"
Form 4 regulatory
"The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did TWST report for Dennis Cho?
Dennis Cho sold 14,205 shares of Twist Bioscience Corp common stock on August 19, 2026. The sale was reported as a Form 4 transaction and coded as a sale in an open market or private transaction.

At what price were Dennis Cho’s TWST shares sold?
The reported sale by Dennis Cho was executed at a price of $129.75 per share. This price is identified as the transaction price per share for the 14,205 shares of common stock sold.

How many TWST shares does Dennis Cho hold after this transaction?
After the reported sale, Dennis Cho directly holds 75,661 TWST common shares. This figure is disclosed as the total number of shares owned following the transaction on August 19, 2026.

Was the TWST insider sale by Dennis Cho under a Rule 10b5-1 plan?
Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by Dennis Cho on February 17, 2026, and the Rule 10b5-1 checkbox is marked as affirmed.

What is Dennis Cho’s role at Twist Bioscience Corp (TWST)?
Dennis Cho is identified as Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp. This role is referenced in the remarks section of the insider ownership report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cho Dennis
(Last)(First)(Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/19/2026S14,205(1)D$129.7575,661D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transaction reported on this Form 4 is effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 17, 2026.
Remarks:
Senior Vice President, Chief Legal Officer & Corporate Secretary
/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho08/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR